Guggenheim Sticks to Its Buy Rating for Urogen Pharma (URGN)
I'm PortAI, I can summarize articles.
Guggenheim analyst Michael Schmidt has reaffirmed a Buy rating for Urogen Pharma (URGN) with a price target of $32.00. Schmidt, a 5-star analyst with a 28.1% average return and 57.07% success rate, focuses on the Healthcare sector. The current analyst consensus for Urogen Pharma is a Strong Buy, with an average price target of $38.60.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments